<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03421132</url>
  </required_header>
  <id_info>
    <org_study_id>M4</org_study_id>
    <nct_id>NCT03421132</nct_id>
  </id_info>
  <brief_title>Multiple Myeloma Molecular Monitoring Study</brief_title>
  <acronym>M4</acronym>
  <official_title>The Terry Fox Pan-Canadian Multiple Myeloma Molecular Monitoring Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Horizon Health Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Horizon Health Network</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will track 250 multiple myeloma patients across Canada over time, using new
      lab tests to evaluate their blood and bone marrow, as they receive standard of care
      treatment. The main hypothesis is that these tests will allow clinicians to better diagnose
      and manage multiple myeloma, improving patients' quality of life overall.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple myeloma (MM) is a deadly cancer of the bone marrow that is challenging to manage and
      treat: the drugs that are currently available attack the cancer in the same way for everyone,
      but each patient has different types of MM cancer cells and different family traits that
      predict better or worse outcomes. As well, the ways in which clinicians test to see if the
      cancer is in remission are not very good at detecting small numbers of cancer cells still in
      the bone marrow after treatment - and which will, sooner or later cause the patient to get
      sick again. The goal of the M4 study is to improve MM patients' survival and quality of life
      over time, by finding better ways of a) characterizing each patient's experience with the
      disease, and b) identifying and tracking the small numbers of cells that remain after
      treatment.

      The investigators plan to track 250 patients across Canada over time, who are getting
      treatment for multiple myeloma. While they are getting treatment, the research team will
      evaluate samples of their blood and bone marrow with newer, more precise laboratory tests.
      Participants will also be asked to take part in two scans of their bodies during their
      treatment. The investigators hypothesize that these tests can help clinicians make better
      treatment recommendations to patients.

      The investigators will look at whether one test is better than another, or if a combination
      of these tests is needed to have the best information possible to make treatment decisions.
      At the same time, the research will also explore how and why some patients' cancer becomes
      resistant to the treatments over time, and how myeloma cells are able to start growing again
      after treatment. The research team will also collect information on how each patient's health
      and quality of life changes during and after treatment, and what are the associated costs
      with these new approaches - to both the healthcare system overall, and to patients.

      Once the five-year research program is complete, it is hoped that clinicians will have a new,
      proven and affordable process of combining these new laboratory tests with the current
      clinical approach, to create new options to evaluate and treat multiple myeloma.

      It is the overall goal that this research will make a difference, right away and across the
      world, in how doctors treat multiple myeloma, in how it is studied by scientists, and in how
      patients advocate for their own healthcare.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2018</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of Minimal Residual Disease (MRD) Assays</measure>
    <time_frame>100 days post-treatment</time_frame>
    <description>Comparison of the sensitivity of two leading-edge MRD assays - (1) multiparameter flow cytometry (MFC), and (2) immunoglobulin gene sequencing (IgS) - in patients who meet the conventional definition of complete remission post-treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitivity of Minimal Residual Disease (MRD) Assays</measure>
    <time_frame>12 months post-maintenance therapy</time_frame>
    <description>Comparison of the sensitivity of two leading-edge MRD assays - (1) multiparameter flow cytometry (MFC), and (2) immunoglobulin gene sequencing (IgS) - in patients who meet the conventional definition of complete remission post-treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of Sensitivity of MRD Assays with PET scans</measure>
    <time_frame>12 months post-maintenance therapy</time_frame>
    <description>Comparison of the sensitivity of two MRD assays - (1) multiparameter flow cytometry (MFC), and (2) immunoglobulin gene sequencing (IgS) - with (3) positron emission tomography (PET) imaging scans, in order to determine if PET scans offer additional information above and beyond that offered through the two assays.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predicting Progression-Free Survival Using MRD Assessment</measure>
    <time_frame>5 years</time_frame>
    <description>Establish the prognostic significance of MRD assessment (i.e., the two MRD assays, and PET scans) on progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predicting Overall Survival Using MRD Assessment</measure>
    <time_frame>5 years</time_frame>
    <description>Establish the prognostic significance of MRD assessment (i.e., the two MRD assays, and PET scans) on overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality-Adjusted Life Years (QALYs) Gained</measure>
    <time_frame>5 years</time_frame>
    <description>To fully understand health care costs and benefits associated with personalized risk-adapted testing and monitoring strategies for cancer, compared to current standard of care (e.g., non-personalized), the investigators will create a model that includes cohort's responses on patient-reported health status (using the EuroQol-5D or EQ-5D-L) and use of healthcare resources (using the NCIC Resource Utilization Form), and that will calculate quality-adjusted life years of the participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental Cost-Effectiveness of MRD Testing</measure>
    <time_frame>5 years</time_frame>
    <description>To fully understand health care costs and benefits associated with personalized risk-adapted testing and monitoring strategies for cancer, compared to current standard of care (e.g., non-personalized), the investigators will create a model that includes cohort's responses on patient-reported health status (using the EuroQol-5D or EQ-5D-L) and use of healthcare resources (using the NCIC Resource Utilization Form), and that will calculate the cost-effectiveness of the MRD assays under investigation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Productivity Costs Associated with MRD Testing</measure>
    <time_frame>5 years</time_frame>
    <description>To fully understand health care costs and benefits associated with personalized risk-adapted testing and monitoring strategies for cancer, compared to current standard of care (e.g., non-personalized), the investigators will create a model that includes cohort's responses on patient-reported health status (using the EuroQol-5D or EQ-5D-L) and use of healthcare resources (using the NCIC Resource Utilization Form), and that will calculate the individual and system-level productivity costs associated with the MRD assays under investigation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Myeloma Patients' Quality of Life (QOL)</measure>
    <time_frame>5 years</time_frame>
    <description>The investigators will evaluate patients' QOL, especially how it is impacted by treatment, disease and patient characteristics, using a common self-report measure (European Organization for Research and Treatment of Cancer - Quality of Life Questionnaire, or EORTC-QLQ-30). Specific outcomes include QOL at each time point in the study and overall for the cohort, comparing those who achieve MRD and those who do not.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlative Study: Sensitivity and Specificity of Drug Resistance Assays</measure>
    <time_frame>5 years</time_frame>
    <description>The investigators will also investigate sensitivity and specificity of assays of drug resistance (e.g., why this cancer eventually becomes resistant to the drugs used to treat it)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlative Study: Circulating Tumor DNA</measure>
    <time_frame>5 years</time_frame>
    <description>The investigators will also investigate prognostic significance of circulating tumour (ct) DNA profiles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlative Study: Describing Myeloma Progenitor Populations</measure>
    <time_frame>5 years</time_frame>
    <description>The investigators will also seek to understand how the cancer recurs and regrows, even for those who achieve an MRD state.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Multiple Myeloma</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Human Peripheral Blood: DNA, RNA and WBC.

      Human Bone Marrow: DNA, RNA, WBC, CD138 positive and CD138 negative cells.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be recruited through hospital oncology clinics across Canada
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to give informed consent

          -  Diagnosed with active multiple myeloma

          -  Consented to participation in Myeloma Canada Research Network (MCRN) database project

          -  Previously untreated and eligible for autologous stem-cell transplantation (ASCT)

        Exclusion Criteria:

          -  Ineligible for ASCT

          -  Does not consent to participate in MCRN database project
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony J Reiman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Horizon Health Network</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bryn A Robinson, PhD</last_name>
    <phone>506-649-2649</phone>
    <email>bryn.robinson@horizonnb.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicole Barry, MA</last_name>
    <phone>506-648-6902</phone>
    <email>nicole.barry@horizonnb.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edith Nsangou</last_name>
      <phone>403-521-3889</phone>
      <email>Edith.Nsangou@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Nizar Bahlis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fareeha Khan</last_name>
      <phone>604-875-4111</phone>
      <phone_ext>22966</phone_ext>
      <email>Fareeha.khan1@bccancer.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Kevin Song, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Darlene Zwarych</last_name>
      <phone>204-787-8805</phone>
      <email>Dzwarych@cancercare.mb.ca</email>
    </contact>
    <investigator>
      <last_name>Rami Kotb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint John Regional Hospital (Horizon Health Network)</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <zip>E2L 4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Barry, MA</last_name>
      <phone>506-648-6902</phone>
      <email>Nicole.Barry@HorizonNB.ca</email>
    </contact>
    <contact_backup>
      <last_name>Bryn Robinson, PhD</last_name>
      <phone>506-649-2649</phone>
      <email>bryn.robinson@horizonnb.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Anthony Reiman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nova Lee Horne</last_name>
      <phone>902-473-7349</phone>
      <email>NovaLee.Horne@nshealth.ca</email>
    </contact>
    <contact_backup>
      <last_name>Blaine Gallant</last_name>
      <phone>902-473-7349</phone>
      <email>Blaine.Gallant@nshealth.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Darrell White, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lynne Cullen</last_name>
      <phone>613-737-8899</phone>
      <phone_ext>73952</phone_ext>
      <email>lycullen@ohri.ca</email>
    </contact>
    <investigator>
      <last_name>Arleigh McCurdy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harminder Paul</last_name>
      <phone>416-946-2317</phone>
      <email>Harminder.Paul@uhnresearch.ca</email>
    </contact>
    <investigator>
      <last_name>Donna Reece, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CIUSSS de l'Est-de-l'Île-de-Montréal (Maisonneuve-Rosemount)</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nathalie Lachapelle</last_name>
      <phone>514-252-3400</phone>
      <phone_ext>4471</phone_ext>
      <email>nlachapelle.hmr@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Richard LeBlanc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Roy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luigina Mollica, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Waller</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>36897</phone_ext>
      <email>daniel.waller@mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Michael Sebag, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chaim Shustik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rayan Kaedbey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Storring, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Avet-Loiseau H, Corre J, Lauwers-Cances V, Chretien M, Robillard N, Leleu X, et al. 191 Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Study. Blood 126(23): 191, 2015.</citation>
  </reference>
  <reference>
    <citation>Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldes C, Lee JJ, Chen C, Oriol A, de la Rubia J, Qiu L, White DJ, Binder D, Anderson K, Fermand JP, Moreau P, Attal M, Knight R, Chen G, Van Oostendorp J, Jacques C, Ervin-Haynes A, Avet-Loiseau H, Hulin C, Facon T; FIRST Trial Team. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014 Sep 4;371(10):906-17. doi: 10.1056/NEJMoa1402551.</citation>
    <PMID>25184863</PMID>
  </reference>
  <reference>
    <citation>Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I, Dawson KJ, Iorio F, Nik-Zainal S, Bignell GR, Hinton JW, Li Y, Tubio JM, McLaren S, O' Meara S, Butler AP, Teague JW, Mudie L, Anderson E, Rashid N, Tai YT, Shammas MA, Sperling AS, Fulciniti M, Richardson PG, Parmigiani G, Magrangeas F, Minvielle S, Moreau P, Attal M, Facon T, Futreal PA, Anderson KC, Campbell PJ, Munshi NC. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014;5:2997. doi: 10.1038/ncomms3997.</citation>
    <PMID>24429703</PMID>
  </reference>
  <reference>
    <citation>Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, Anderson KC, Ardlie KG, Auclair D, Baker A, Bergsagel PL, Bernstein BE, Drier Y, Fonseca R, Gabriel SB, Hofmeister CC, Jagannath S, Jakubowiak AJ, Krishnan A, Levy J, Liefeld T, Lonial S, Mahan S, Mfuko B, Monti S, Perkins LM, Onofrio R, Pugh TJ, Rajkumar SV, Ramos AH, Siegel DS, Sivachenko A, Stewart AK, Trudel S, Vij R, Voet D, Winckler W, Zimmerman T, Carpten J, Trent J, Hahn WC, Garraway LA, Meyerson M, Lander ES, Getz G, Golub TR. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011 Mar 24;471(7339):467-72. doi: 10.1038/nature09837.</citation>
    <PMID>21430775</PMID>
  </reference>
  <reference>
    <citation>Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet-Loiseau H; International Myeloma Working Group. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014 Feb;28(2):269-77. doi: 10.1038/leu.2013.247. Epub 2013 Aug 26. Review.</citation>
    <PMID>23974982</PMID>
  </reference>
  <reference>
    <citation>Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004 Aug 19;351(8):781-91.</citation>
    <PMID>15317891</PMID>
  </reference>
  <reference>
    <citation>González D, van der Burg M, García-Sanz R, Fenton JA, Langerak AW, González M, van Dongen JJ, San Miguel JF, Morgan GJ. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood. 2007 Nov 1;110(9):3112-21. Epub 2007 Jul 18. Review.</citation>
    <PMID>17634408</PMID>
  </reference>
  <reference>
    <citation>Kapoor P, Kumar SK, Dispenzieri A, Lacy MQ, Buadi F, Dingli D, Russell SJ, Hayman SR, Witzig TE, Lust JA, Leung N, Lin Y, Zeldenrust SR, McCurdy A, Greipp PR, Kyle RA, Rajkumar SV, Gertz MA. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol. 2013 Dec 20;31(36):4529-35. doi: 10.1200/JCO.2013.49.0086. Epub 2013 Nov 18.</citation>
    <PMID>24248686</PMID>
  </reference>
  <reference>
    <citation>Korde N, Roschewski M, Zingone A, Kwok M, Manasanch EE, Bhutani M, Tageja N, Kazandjian D, Mailankody S, Wu P, Morrison C, Costello R, Zhang Y, Burton D, Mulquin M, Zuchlinski D, Lamping L, Carpenter A, Wall Y, Carter G, Cunningham SC, Gounden V, Sissung TM, Peer C, Maric I, Calvo KR, Braylan R, Yuan C, Stetler-Stevenson M, Arthur DC, Kong KA, Weng L, Faham M, Lindenberg L, Kurdziel K, Choyke P, Steinberg SM, Figg W, Landgren O. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. JAMA Oncol. 2015 Sep;1(6):746-54. doi: 10.1001/jamaoncol.2015.2010.</citation>
    <PMID>26181891</PMID>
  </reference>
  <reference>
    <citation>Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6. Review.</citation>
    <PMID>27511158</PMID>
  </reference>
  <reference>
    <citation>Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, Chung KC, Tiedemann RE. Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma. Cancer Cell. 2015 Oct 12;28(4):541-542. doi: 10.1016/j.ccell.2015.09.010. Epub 2015 Oct 12.</citation>
    <PMID>28854350</PMID>
  </reference>
  <reference>
    <citation>Mailankody S, Korde N, Lesokhin AM, Lendvai N, Hassoun H, Stetler-Stevenson M, Landgren O. Minimal residual disease in multiple myeloma: bringing the bench to the bedside. Nat Rev Clin Oncol. 2015 May;12(5):286-95. doi: 10.1038/nrclinonc.2014.239. Epub 2015 Jan 27. Review.</citation>
    <PMID>25622976</PMID>
  </reference>
  <reference>
    <citation>Martinez-Lopez J, Lahuerta JJ, Pepin F, González M, Barrio S, Ayala R, Puig N, Montalban MA, Paiva B, Weng L, Jiménez C, Sopena M, Moorhead M, Cedena T, Rapado I, Mateos MV, Rosiñol L, Oriol A, Blanchard MJ, Martínez R, Bladé J, San Miguel J, Faham M, García-Sanz R. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014 May 15;123(20):3073-9. doi: 10.1182/blood-2014-01-550020. Epub 2014 Mar 19.</citation>
    <PMID>24646471</PMID>
  </reference>
  <reference>
    <citation>Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I, McNiece I, Lin L, Ambinder RF, Peacock C, Watkins DN, Huff CA, Jones RJ. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 2008 Jan 1;68(1):190-7. doi: 10.1158/0008-5472.CAN-07-3096.</citation>
    <PMID>18172311</PMID>
  </reference>
  <reference>
    <citation>Moreau P, Attal M, Caillot D, Macro M, Karlin L, Garderet L, Facon T, Benboubker L, Escoffre-Barbe M, Stoppa AM, Laribi K, Hulin C, Perrot A, Marit G, Eveillard JR, Caillon F, Bodet-Milin C, Pegourie B, Dorvaux V, Chaleteix C, Anderson K, Richardson P, Munshi NC, Avet-Loiseau H, Gaultier A, Nguyen JM, Dupas B, Frampas E, Kraeber-Bodere F. Prospective Evaluation of Magnetic Resonance Imaging and [(18)F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. J Clin Oncol. 2017 Sep 1;35(25):2911-2918. doi: 10.1200/JCO.2017.72.2975. Epub 2017 Jul 7.</citation>
    <PMID>28686535</PMID>
  </reference>
  <reference>
    <citation>Nygaard AD, Garm Spindler KL, Pallisgaard N, Andersen RF, Jakobsen A. The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer. Lung Cancer. 2013 Mar;79(3):312-7. doi: 10.1016/j.lungcan.2012.11.016. Epub 2012 Dec 11.</citation>
    <PMID>23238036</PMID>
  </reference>
  <reference>
    <citation>Paiva B, Vidriales MB, Cerveró J, Mateo G, Pérez JJ, Montalbán MA, Sureda A, Montejano L, Gutiérrez NC, García de Coca A, de Las Heras N, Mateos MV, López-Berges MC, García-Boyero R, Galende J, Hernández J, Palomera L, Carrera D, Martínez R, de la Rubia J, Martín A, Bladé J, Lahuerta JJ, Orfao A, San Miguel JF; GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Groups. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008 Nov 15;112(10):4017-23. doi: 10.1182/blood-2008-05-159624. Epub 2008 Jul 31.</citation>
    <PMID>18669875</PMID>
  </reference>
  <reference>
    <citation>Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014 Nov;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26. Review.</citation>
    <PMID>25439696</PMID>
  </reference>
  <reference>
    <citation>Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Feyler S, Ross FM, Cook G, Jackson GH, Morgan GJ, Owen RG. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol. 2013 Jul 10;31(20):2540-7. doi: 10.1200/JCO.2012.46.2119. Epub 2013 Jun 3. Erratum in: J Clin Oncol. 2013 Dec 1;31(34):4383.</citation>
    <PMID>23733781</PMID>
  </reference>
  <reference>
    <citation>Rawstron AC, Gregory WM, de Tute RM, Davies FE, Bell SE, Drayson MT, Cook G, Jackson GH, Morgan GJ, Child JA, Owen RG. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. Blood. 2015 Mar 19;125(12):1932-5. doi: 10.1182/blood-2014-07-590166. Epub 2015 Feb 2.</citation>
    <PMID>25645353</PMID>
  </reference>
  <reference>
    <citation>Reinert T, Schøler LV, Thomsen R, Tobiasen H, Vang S, Nordentoft I, Lamy P, Kannerup AS, Mortensen FV, Stribolt K, Hamilton-Dutoit S, Nielsen HJ, Laurberg S, Pallisgaard N, Pedersen JS, Ørntoft TF, Andersen CL. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut. 2016 Apr;65(4):625-34. doi: 10.1136/gutjnl-2014-308859. Epub 2015 Feb 4.</citation>
    <PMID>25654990</PMID>
  </reference>
  <reference>
    <citation>Roschewski M, Dunleavy K, Pittaluga S, Moorhead M, Pepin F, Kong K, Shovlin M, Jaffe ES, Staudt LM, Lai C, Steinberg SM, Chen CC, Zheng J, Willis TD, Faham M, Wilson WH. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. 2015 May;16(5):541-9. doi: 10.1016/S1470-2045(15)70106-3. Epub 2015 Apr 1. Erratum in: Lancet Oncol. 2015 May;16(5):e199.</citation>
    <PMID>25842160</PMID>
  </reference>
  <reference>
    <citation>Schwarzenbach H, Eichelser C, Kropidlowski J, Janni W, Rack B, Pantel K. Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression. Clin Cancer Res. 2012 Oct 15;18(20):5719-30. doi: 10.1158/1078-0432.CCR-12-0142. Epub 2012 Sep 25.</citation>
    <PMID>23014523</PMID>
  </reference>
  <reference>
    <citation>Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011 Jun;11(6):426-37. doi: 10.1038/nrc3066. Epub 2011 May 12. Review.</citation>
    <PMID>21562580</PMID>
  </reference>
  <reference>
    <citation>Silva JM, Silva J, Sanchez A, Garcia JM, Dominguez G, Provencio M, Sanfrutos L, Jareño E, Colas A, España P, Bonilla F. Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. Clin Cancer Res. 2002 Dec;8(12):3761-6.</citation>
    <PMID>12473587</PMID>
  </reference>
  <reference>
    <citation>Vij R, Mazumder A, Klinger M, O'Dea D, Paasch J, Martin T, Weng L, Park J, Fiala M, Faham M, Wolf J. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients. Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):131-139.e1. doi: 10.1016/j.clml.2013.09.013. Epub 2013 Oct 2.</citation>
    <PMID>24629890</PMID>
  </reference>
  <reference>
    <citation>Zamagni E, Nanni C, Mancuso K, Tacchetti P, Pezzi A, Pantani L, Zannetti B, Rambaldi I, Brioli A, Rocchi S, Terragna C, Martello M, Marzocchi G, Borsi E, Rizzello I, Fanti S, Cavo M. PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma. Clin Cancer Res. 2015 Oct 1;21(19):4384-90. doi: 10.1158/1078-0432.CCR-15-0396. Epub 2015 Jun 15.</citation>
    <PMID>26078390</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2018</study_first_submitted>
  <study_first_submitted_qc>February 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2018</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Horizon Health Network</investigator_affiliation>
    <investigator_full_name>Dr. Anthony Reiman</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

